enVVeno Medical Corp NVNO
Medical Corporation is a medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve
the standard of care for the treatment of venous disease. Chronic Venous Disease ("CVD") is the world's most prevalent
chronic disease, impacting approximately 70% of the adult population of the U.S. Chronic Venous Insufficiency ("CVI"), is
a large subset of CVD, which most often occurs when valves inside of the veins of the leg become damaged, resulting in the backwards
Last close
6.65
2026-10-23
Market cap
$4.5M
2026-06-30 share count
52-week range
6.55 - 26.25
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-33.06
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $31.2K | $186.6K | $422.1K | — |
| Cost of revenue | — | — | — | — | — | — | — | — | $419.7K | — |
| Gross profit | — | — | — | — | — | — | — | $186.6K | $2.5K | — |
| R&D | $10.0M | $12.2M | $13.6M | $9.9M | $5.7M | $4.3M | $2.2M | $1.2M | $649.7K | — |
| SG&A | $10.9M | $11.6M | $11.7M | $15.0M | $11.2M | $4.9M | $4.9M | $6.5M | $5.5M | — |
| Operating income | -$20.9M | -$23.8M | -$25.2M | -$24.9M | -$16.9M | -$9.1M | -$7.7M | -$7.9M | -$6.1M | — |
| Interest expense | — | — | — | $161.0K | $19.0K | $3.7K | $49.9K | $298.2K | — | — |
| Pre-tax income | -$19.5M | -$21.8M | — | — | — | — | — | — | — | — |
| Net income | -$19.5M | -$21.8M | -$23.5M | -$24.7M | -$16.5M | -$9.1M | -$7.6M | -$13.0M | -$7.8M | — |
| EPS, basic | -33.06 | -44.53 | -1.91 | -2.20 | -1.90 | — | — | — | — | — |
| EPS, diluted | -33.06 | -44.53 | -1.91 | -2.20 | -1.90 | -7.54 | -12.10 | -1.75 | -1.35 | — |
| Shares, diluted (wtd. avg.) | 589,000 | 490,000 | 12.3M | 11.2M | 8.7M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.1M | $1.8M | $3.6M | $4.6M | $54.7M | $9.3M | $1.3M | $2.7M | $77.7K | $56.5K |
| Short-term investments | $25.1M | $41.4M | $42.8M | $34.5M | — | — | — | — | — | — |
| Receivables | — | — | — | — | — | — | — | $32.0K | $35.2K | — |
| Total current assets | $28.8M | $43.7M | $46.9M | $39.4M | $55.0M | $9.6M | $1.4M | $2.8M | $170.4K | — |
| Property, plant and equipment | $51.0K | $182.0K | $334.0K | $521.0K | $618.0K | $399.0K | $344.0K | $26.2K | $23.8K | — |
| Other intangibles | — | — | — | — | — | — | — | $666.5K | $1.1M | — |
| Total assets | $29.6M | $45.0M | $48.6M | $41.7M | $57.7M | $10.5M | $3.4M | $3.6M | $2.2M | — |
| Accounts payable | $358.0K | $1.0M | $1.0M | $1.2M | $560.0K | $1.4M | $1.2M | $1.1M | $1.5M | — |
| Total current liabilities | $2.1M | $2.1M | $1.4M | $1.5M | $1.6M | $3.2M | $1.9M | $1.5M | — | — |
| Total liabilities | $2.4M | $2.8M | $2.4M | $2.9M | $3.3M | $3.4M | $2.4M | $1.5M | $8.2M | — |
| Retained earnings | -$171.3M | -$151.9M | -$130.0M | -$106.5M | -$81.9M | -$65.3M | -$56.2M | -$48.6M | -$35.5M | — |
| Total equity | $27.1M | $42.2M | $46.2M | $38.7M | $54.4M | $7.1M | $989.9K | $2.0M | -$11.1M | -$4.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.6M | -$16.8M | -$18.9M | -$15.6M | -$11.8M | -$7.7M | -$5.9M | -$6.4M | -$4.2M | — |
| Depreciation and amortisation | $100.0K | $200.0K | $200.0K | $200.0K | $100.0K | $100.0K | $46.0K | $10.1K | $15.9K | — |
| Stock-based compensation | $3.4M | $4.1M | $5.2M | $9.0M | $6.0M | $881.2K | $942.0K | $1.9M | $878.4K | — |
| Capital expenditure | $5.0K | $37.0K | $33.0K | $115.0K | $368.0K | $180.3K | $363.9K | $12.4K | $10.9K | — |
| Investing cash flow | $15.9M | $1.3M | -$7.9M | -$34.6M | -$368.0K | -$180.3K | -$363.9K | -$12.4K | $165.3K | — |
| Financing cash flow | $1.0M | $13.6M | $25.8M | — | $57.6M | $15.1M | $5.6M | $9.0M | $4.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012928.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $422.1K | $186.6K | $31.2K | — | — | — | — | — | — |
| Gross profit | — | $2.5K | $186.6K | — | — | — | — | — | — | — |
| Net income | — | -$7.8M | -$13.0M | -$7.6M | -$9.1M | -$16.5M | -$24.7M | -$23.5M | -$21.8M | -$19.5M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Charter or fiscal year changed Item 5.03
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |